Colombian Research Involving Cannabiods For Cancer Patients & Pharmaceutical Products Heats Up - Company Announces Appointment of Well Known Medical Marijuana Scientific Advisor
CORAL SPRINGS, Florida, April 22, 2014 /PRNewswire/ --
Cannabis advancers making strides in product developments and research events: New Colombia Resources, Inc. (OTC: NEWC), Cannabis Science, Inc. (OTC: CBIS), Medical Marijuana, Inc. (OTC: MJNA), Easton Pharmaceuticals, Inc. (OTC: EAPH), Extreme Biodiesel, Inc. (OTC: XTRM) and Next Generation Energy Corp. (OTC: NGMC)
New Colombia Resources, Inc. (OTCQB: NEWC) a U.S. company with coal and other resource assets in Colombia, is pleased to announce the appointment of Dr. Robert J. Melamede PhD, President of Cannabis Science, Inc. (OTC Pink: CBIS), as a scientific advisor to gain approval to legally research and market cannabis based pharmaceutical products in Colombia and other Latin American countries. The Company is discussing a collaborative effort with Cannabis Science, Inc. Dr. Melamede, retired Chairman of the Biology department of the University of Colorado at Colorado Springs, is a world renowned leader in Cannabis research with many years investigating the human body's endocannabinoid system and its reaction to cannabinoids. Dr. Melamede has made many presentations around the globe explaining the benefits of cannabinoids for cancer patients..
To read the full press release, please click here:http://www.fnmprofiles.com/profiles-newc.html
Dr. Melamede, retired Chairman of the Biology department of the University of Colorado at Colorado Springs, is a world renowned leader in Cannabis research with many years investigating the human body s endocannabinoid system and its reaction to cannabinoids. Dr. Melamede has made many presentations around the globe explaining the benefits of cannabinoids for cancer patients. New Colombia Resources will form a joint venture to include U.S. and Colombian investors, universities, and pharmaceutical partners. New Colombia will work closely with government agencies to allow them permission to conduct research of cannabis based formulations. They will hire a reputable law firm to handle government approvals, lobbying, and public relations. The joint venture will conduct studies in different regions of Colombia with high incidences of the specific illness for which treatment is being researched without regard to socio-economic status
Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting recently announced plans to enter the State of Nevada where new law expands medical cannabis opportunities to research, grows, and dispensaries. As the Company has created a partnership in Michigan to advance state cannabis law and pursue state-wide initiatives in Michigan, Cannabis Science intends to bring its know how and resources to Nevada, the state of Cannabis Science's Incorporation. The new law marks another milestone in the progression in the legalization process of the medical cannabis industry in the United States -- one that is aimed at ways of managing multiple ailments for patients. In addition, the new law is expected to contribute to the creation of new sources of revenue and employment opportunities within the state. Cannabis Science is well positioned to bring novel patient-based initiatives to Nevada.
Medical Marijuana, Inc. (OTC Pink: MJNA) operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company's services include development of cannabinoid based health and wellness products; and development of medical grade compounds; and licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. It also offers pre-and-post production tracking, gemplasm references, and packaging and processing services. On Monday, MJNA closed up 2.33% on over 12.7 million shares traded.
Easton Pharmaceuticals, Inc. (OTC Pink: EAPH) recently announced that BMV Medica, S.A. de C.V., a Mexican regulatory company and distributor of pharmaceutical products have signed an exclusive agreement to distribute Easton's "VIORRA" product in Mexico. Carla Pepe, CEO of Easton Pharmaceuticals, stated, "BMV Medica, as previously announced, is the company's current regulatory consultant for Mexico and other parts of Latin America. After extensive discussions Easton has finalized a deal whereby BMV Medica will take over Marketing and Distribution for VIORRA." Mrs. Pepe further commented, "They have shown a strong interest in the growth of VIORRA in Mexico, and expect to launch VIORRA later this year, subject to the regulatory approvals and finalizing the sourcing out of a suitable manufacturing partner. Discussions with possible manufacturers are well under way and BMV anticipates finalizing a deal shortly."
Extreme Biodiesel, Inc. (OTC Pink: XTRM) recently announced the following corporate update to shareholders. The Company has executed a one year lease with one year option on a satellite facility to produce XTRM's Proprietary Mobile Biodiesel Unit / Hemp To Biodiesel Unit. The location of the facility is at 28030 Hwy 74, Lake Elsinore, CA 92570. It houses an office, a working garage, along with the additional space needed for storage of biodiesel equipment. Company President Joseph Spadafore stated "Demand for the Mobile Biodiesel Unit has been decent, we hope that this facility which is within about an hour from the 40 acre project XTRM is developing will help lower the production cost of the unit and result in increased sales."
Next Generation Energy Corp. (OTCQB: NGMC) wholly owned subsidiary, NextGen Cannabis Consulting, LLC, recently announced it has retained a prominent California law firm whose varied areas of practice include significant knowledge and background about the medical marijuana industry. NextGen Cannabis has retained the law offices of Ariel Clark to assist it with its business plan to enter the fast growing medical marijuana industry. "We have steadily built a strong management team and industry relationships to aggressively profit from this industry. Exceptional legal talent is equally important to our success and I am extremely pleased to have Ariel Clark and her firm representing NGMC," said Darryl Reed, CEO.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has not been compensated for news coverage of the current press release issued by New Colombia Resources, Inc..but expects compensation which will be fully disclosed at that time.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group LLC